Skip to main content

Advertisement

SpringerLink
Log in

Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event of cancer treatment; however, no drug is recommended for the prevention of CIPN. In Japan, several drugs such as Gosha-Jinki-Gan and duloxetine are frequently administered as a treatment for CIPN. The aim of this study was to elucidate prescription patterns of drugs administered for CIPN caused by oxaliplatin and the association between these drugs and the duration of oxaliplatin treatment.

Methods

We conducted a retrospective nationwide study using the JMDC administrative claims database (January 2005–June 2020; JMDC Inc., Japan). Patients newly treated with oxaliplatin were identified, and prescription patterns of CIPN medication including Gosha-Jinki-Gan, pregabalin, duloxetine, mecobalamin, and mirogabalin were investigated. The primary outcome was the duration of oxaliplatin treatment. Multivariable logistic regression analysis was performed to examine the association between CIPN medication and duration of oxaliplatin treatment.

Results

A total of 4,739 patients who newly received oxaliplatin were identified. Of these, 759 (16.0%) had received CIPN medication. Duloxetine was administered in 99 (2.1%) patients. Multivariable logistic regression analysis revealed that CIPN medication was significantly associated with the prolonged duration of oxaliplatin treatment (odds ratio: 2.35, [95% confidence interval: 1.99–2.77]).

Conclusion

Real-world data demonstrated that the administration rate of CIPN medication was higher in patients who received oxaliplatin treatment for over 6 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Availability of data and material

All data generated or analyzed during this study are included in this published article.

Code availability

Not applicable.

References

  1. Argyriou AA, Bruna J, Marmiroli P et al (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82:51–77. https://doi.org/10.1016/j.critrevonc.2011.04.012

    Article  PubMed  Google Scholar 

  2. Seretny M, Currie GL, Sena ES et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155:2461–2470. https://doi.org/10.1016/j.pain.2014.09.020

    Article  PubMed  Google Scholar 

  3. Yamamoto S, Egashira N (2020) Drug repositioning for the prevention and treatment of chemotherapy-induced peripheral neuropathy: a mechanism- and screening-based strategy. Front Pharmacol 11:607780. https://doi.org/10.3389/fphar.2020.607780

    Article  CAS  PubMed  Google Scholar 

  4. Hirayama Y, Yoshida Y, Mori M et al (2020) Effects of the publication of Clinical Guidelines for the Management of Chemotherapy-Induced Peripheral Neuropathy on the Administration Preferences of Oncology Specialists: Japanese Association of Supportive Care in Cancer. Jpn J Clin Oncol 50:897–902. https://doi.org/10.1093/jjco/hyaa056

    Article  PubMed  Google Scholar 

  5. Loprinzi CL, Lacchetti C, Bleeker J et al (2020) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 38:3325–3348. https://doi.org/10.1200/jco.20.01399

    Article  PubMed  Google Scholar 

  6. Jordan B, Margulies A, Cardoso F et al (2020) Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol 31:1306–1319. https://doi.org/10.1016/j.annonc.2020.07.003

    Article  CAS  PubMed  Google Scholar 

  7. Park SB, Lin CSY, Krishnan AV et al (2011) Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist 16:708–716. https://doi.org/10.1634/theoncologist.2010-0248

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Kawashiri T, Mine K, Kobayashi D et al (2021) Therapeutic agents for oxaliplatin-induced peripheral neuropathy; experimental and clinical evidence. Int J Mol Sci 22. https://doi.org/10.3390/ijms22031393

  9. Kimura S, Sato T, Ikeda S et al (2010) Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol 20:413–419. https://doi.org/10.2188/jea.je20090066

    Article  PubMed  PubMed Central  Google Scholar 

  10. Nagai K, Tanaka T, Kodaira N et al (2021) Data resource profile: JMDC claims database sourced from health insurance societies. J Gen Fam Med 22:118–127. https://doi.org/10.1002/jgf2.422

    Article  PubMed  PubMed Central  Google Scholar 

  11. André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116. https://doi.org/10.1200/jco.2008.20.6771

    Article  PubMed  Google Scholar 

  12. Haller DG, Tabernero J, Maroun J et al (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29:1465–1471. https://doi.org/10.1200/jco.2010.33.6297

    Article  CAS  PubMed  Google Scholar 

  13. Bang YJ, Kim YW, Yang HK et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321. https://doi.org/10.1016/s0140-6736(11)61873-4

    Article  CAS  PubMed  Google Scholar 

  14. Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367. https://doi.org/10.1001/jama.2013.2813

    Article  PubMed  PubMed Central  Google Scholar 

  15. Argyriou AA, Velasco R, Briani C et al (2012) Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 23:3116–3122. https://doi.org/10.1093/annonc/mds208

    Article  CAS  PubMed  Google Scholar 

  16. Tanishima H, Tominaga T, Kimura M et al (2017) Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy. Support Care Cancer 25:1383–1389. https://doi.org/10.1007/s00520-016-3514-6

    Article  PubMed  Google Scholar 

  17. Ali NT, Mohamed AA, Yousef BA (2020) The incidence of oxaliplatin-induced peripheral neurotoxicity at Khartoum Oncology Hospital: a cross-sectional survey. Asia Pac J Oncol Nurs 7:266–272. https://doi.org/10.4103/apjon.apjon_12_20

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ibrahim EY, Ehrlich BE (2020) Prevention of chemotherapy-induced peripheral neuropathy: a review of recent findings. Crit Rev Oncol Hematol 145:102831. https://doi.org/10.1016/j.critrevonc.2019.102831

    Article  PubMed  Google Scholar 

  19. Japanese Association of Supportive Care in Cancer (2017). Clinical guide of management for chemotherapy-induced peripheral neuropathy. KANEHARA & Co. Ltd., in Japanese, Tokyo

  20. Żok J, Bieńkowski M, Radecka B et al (2021) Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort study. BMC Cancer 21:529. https://doi.org/10.1186/s12885-021-08183-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Gu J, Lu H, Chen C et al (2021) Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis. Support Care Cancer. https://doi.org/10.1007/s00520-021-06321-7

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hoshino N, Ganeko R, Hida K et al (2018) Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Int J Clin Oncol 23:434–442. https://doi.org/10.1007/s10147-017-1229-4

    Article  CAS  PubMed  Google Scholar 

  23. Oki E, Emi Y, Kojima H et al (2015) Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. Int J Clin Oncol 20:767–775. https://doi.org/10.1007/s10147-015-0784-9

    Article  CAS  PubMed  Google Scholar 

  24. Kuriyama A, Endo K (2018) Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Support Care Cancer 26:1051–1059. https://doi.org/10.1007/s00520-017-4028-6

    Article  PubMed  Google Scholar 

  25. de Andrade DC, Jacobsen Teixeira M, Galhardoni R et al (2017) Pregabalin for the prevention of oxaliplatin-induced painful neuropathy: a randomized, double-blind trial. Oncologist 22:1154-e105. https://doi.org/10.1634/theoncologist.2017-0235

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hirayama Y, Ishitani K, Sato Y et al (2015) Effect of duloxetine in Japanese patients with chemotherapy-induced peripheral neuropathy: a pilot randomized trial. Int J Clin Oncol 20:866–871. https://doi.org/10.1007/s10147-015-0810-y

    Article  CAS  PubMed  Google Scholar 

  27. Tournigand C, Cervantes A, Figer A et al (2006) OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer–a GERCOR study. J Clin Oncol 24:394–400. https://doi.org/10.1200/jco.2005.03.0106

    Article  CAS  PubMed  Google Scholar 

  28. Samuels N, Ben-Arye E (2020) Integrative approaches to chemotherapy-induced peripheral neuropathy. Curr Oncol Rep 22:23. https://doi.org/10.1007/s11912-020-0891-2

    Article  PubMed  Google Scholar 

Download references

Funding

This work was supported by JSPS KAKENHI (Grant no. JP19K16461).

Author information

Authors and Affiliations

  1. Division of Drug Informatics, School of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashiosaka City, Osaka, 577-8502, Japan

    Satoshi Yokoyama, Chihiro Nakagawa & Kouichi Hosomi

Authors
  1. Satoshi Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chihiro Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kouichi Hosomi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study’s conception and design. Material preparation, data collection and analysis were performed by Satoshi Yokoyama and Chihiro Nakagawa. Analysis and interpretation of data were performed by Satoshi Yokoyama, Chihiro Nakagawa, and Kouichi Hosomi. The first draft of the manuscript was written by Satoshi Yokoyama, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Satoshi Yokoyama.

Ethics declarations

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yokoyama, S., Nakagawa, C. & Hosomi, K. Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study. Support Care Cancer 30, 1765–1773 (2022). https://doi.org/10.1007/s00520-021-06585-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-021-06585-z

Keywords

Search

Navigation